Frovatriptan: Difference between revisions

Jump to navigation Jump to search
mNo edit summary
mNo edit summary
Line 4: Line 4:
{{CMG}}; {{AE}} {{SS}}
{{CMG}}; {{AE}} {{SS}}


'''''For patient information about Frovatriptan, click [[Frovatriptan (patient information)|here]]'''''
'''''For patient information about Frovatriptan, click [[Frovatriptan (patient information)|here]].'''''


{{SB}} FROVA<sup>®</sup>
{{SB}} FROVA<sup>®</sup>

Revision as of 22:32, 9 February 2014

Frovatriptan
FROVA® FDA Package Insert
Indications and Usage
Dosage and Administration
Dosage Forms and Strengths
Contraindications
Warnings and Precautions
Adverse Reactions
Drug Interactions
Use in Specific Populations
Overdosage
Description
Clinical Pharmacology
Nonclinical Toxicology
Clinical Studies
How Supplied/Storage and Handling
Patient Counseling Information
Labels and Packages
Clinical Trials on Frovatriptan
ClinicalTrials.gov

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sheng Shi, M.D. [2]

For patient information about Frovatriptan, click here.

Synonyms / Brand Names: FROVA®

Overview

Frovatriptan (trade name Frova) is a triptan drug developed by Vernalis for the treatment of migraineheadaches, in particular those associated with menstruation. The product is licensed to Endo Pharmaceuticals in North America andMenarini in Europe.[1]

Category

Antimigraine Drugs, Triptans

FDA Package Insert

Indications and Usage | Dosage and Administration | Dosage Forms and Strengths | Contraindications | Warnings and Precautions | Adverse Reactions | Drug Interactions | Use in Specific Populations | Overdosage | Description | Clinical Pharmacology | Nonclinical Toxicology | Clinical Studies | How Supplied/Storage and Handling | Patient Counseling Information | Labels and Packages

Mechanism of Action

Frovatriptan binds with high affinity to 5-HT1B/1D receptors. The therapeutic activity of FROVA is thought to be due to the agonist effects at the 5-HT1B/1D receptors on intracranial blood vessels (including the arterio-venous anastomoses) and sensory nerves of the trigeminal system which result in cranial vessel constriction and inhibition of pro-inflammatory neuropeptide release.

References

  1. "Frova". Vernalis. Retrieved 2007-11-28.


Template:WikiDoc Sources